VTVT - vTv Therapeutics Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.820
-0.010 (-1.19%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.830
Open0.824
Bid0.790 x 800
Ask0.820 x 1100
Day's Range0.780 - 0.830
52 Week Range0.650 - 8.400
Volume116,015
Avg. Volume144,607
Market Cap30.329M
Beta1.66
PE Ratio (TTM)N/A
EPS (TTM)-1.429
Earnings DateOct 31, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • Business Wire21 days ago

    vTv Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

    vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 4-6, 2018, at The St. Regis Hotel in New York City. vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. This release contains forward-looking statements, which involve risks and uncertainties.

  • VTV CEO on Alzheimer's drug: "We have not given up on it"
    American City Business Journals29 days ago

    VTV CEO on Alzheimer's drug: "We have not given up on it"

    A closer look at data from two clinical trials reveals what company executives believe is potential for vTv Therapeutics's investigational Alzheimer's drug to get FDA approval for further testing.

  • VTv Therapeutics (VTVT) Reports Q2 Loss, Tops Revenue Estimates
    Zacks2 months ago

    VTv Therapeutics (VTVT) Reports Q2 Loss, Tops Revenue Estimates

    vTv Therapeutics (VTVT) delivered earnings and revenue surprises of -16.00% and 0.69%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    VTv Therapeutics: 2Q Earnings Snapshot

    On a per-share basis, the High Point, North Carolina-based company said it had a loss of 31 cents. Losses, adjusted for non-recurring costs, came to 29 cents per share. The results fell short of Wall Street ...

  • Business Wire2 months ago

    vTv Therapeutics Announces Second Quarter 2018 Results and Update

    vTv Therapeutics Inc. today reported financial results for the second quarter that ended June 30, 2018, and provided an update on recent achievements and upcoming events.

  • ACCESSWIRE2 months ago

    Breakfast Technical Briefing on ZIOPHARM Oncology and Three Other Additional Biotech Stocks

    For today, WallStEquities.com assesses vTv Therapeutics Inc. (NASDAQ: VTVT), Voyager Therapeutics Inc. (NASDAQ: VYGR), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Zosano Pharma Corp. (NASDAQ: ZSAN). High Point, North Carolina headquartered vTv Therapeutics Inc.'s stock saw a decline of 3.70%, finishing last Friday's trading session at $1.30. The Company's shares are trading below their 50-day moving average by 19.58%.

  • ACCESSWIRE3 months ago

    Initiating Free Research Reports on ZIOPHARM Oncology and Three Other Biotech Equities

    Stock Research Monitor: VYGR, VTVT, and ZSAN LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on ZIOP sign up now at www.wallstequities.com/registration . WallStEquities.com recalls ...

  • Business Wire3 months ago

    vTv Therapeutics to Present a Poster at the American Diabetes Association’s 78th Scientific Sessions

    vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that Company management will present a poster featuring vTv Therapeutics’ liver-selective Glucokinase Activator at the American Diabetes Association’s 78th Scientific Sessions held in Orlando, Fla., June 22–26, 2018. “As the first company to evaluate a Glucokinase Activator in people with type 1 diabetes, we are very excited to be sharing this clinical data at the American Diabetes Association’s 78th Scientific Sessions,” said Carmen Valcarce, Ph.D., executive vice president, chief scientific officer, vTv Therapeutics.

  • Business Wire3 months ago

    vTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study

    vTv Therapeutics Inc. (VTVT) today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints. The prespecified subgroup consisted of azeliragon-treated patients with maximal azeliragon plasma concentrations of less than 7.5 ng/mL and baseline Mini Mental State Examination (MMSE) scores between 19 and 27, and the endpoints were statistically significant improvement in cognitive or functional outcomes as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) at 12-months compared to placebo.

  • vTv Therapeutics (VTVT) Catches Eye: Stock Jumps 6.9%
    Zacks4 months ago

    vTv Therapeutics (VTVT) Catches Eye: Stock Jumps 6.9%

    vTv Therapeutics (VTVT) shares rose nearly 7% in the last trading session, amid huge volumes.

  • VTv Therapeutics inks licensing agreement with Chinese biotech firm
    American City Business Journals4 months ago

    VTv Therapeutics inks licensing agreement with Chinese biotech firm

    High Point-based vTv Therapeutics has inked an agreement with a Chinese company for rights to develop and commercialize a drug candidate aimed at respiratory and other inflammatory diseases. China’s Newsoara Biopharma Co. Ltd. has acquired rights for HPP737, a selective phosphodiesterase type 4 (PDE4) inhibitor, that has shown therapeutic activity in several animal models for inflammation. It will be able to commercialize the product in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries covering Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei and South Korea.

  • Business Wire4 months ago

    vTv Therapeutics Announces Licensing Agreement with Newsoara Biopharma Co. Ltd. to Rights for vTv’s PDE4 Inhibitor in China and Other Pacific Rim Territories

    vTv Therapeutics Inc. (VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries covering Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei and South Korea. Under the terms of the agreement, vTv Therapeutics will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products. Newsoara will develop HPP737 in the covered territories for respiratory and other inflammatory diseases.

  • ACCESSWIRE4 months ago

    Complimentary Technical Snapshots on VIVUS and Three More Biotech Stocks

    Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79.

  • Associated Press4 months ago

    VTv Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the High Point, North Carolina-based company said it had a loss of 30 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • Business Wire4 months ago

    vTv Therapeutics Reports 2018 First Quarter Financial and Operational Results and Recent Highlights

    vTv Therapeutics Inc. today reported financial and operational results for the first quarter that ended March 31, 2018.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: vTv Therapeutics and ARCA Biopharma

    NEW YORK, NY / ACCESSWIRE / May 11, 2018 / vTv Therapeutics and ARCA biopharma were both soaring in Thursday's trading session. Both had news as catalysts to drive shares higher with vTv Therapeutics announcing ...

  • Business Wire4 months ago

    vTv Therapeutics Announces Company will Pre-specify New Subgroup with the FDA and Report Phase 3 Part B Results in June

    vTv Therapeutics Inc. (VTVT) today announced that based on post-hoc analyses of the data from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease, despite not meeting co-primary endpoints, identified a subpopulation that showed statistically significant benefit (unadjusted for multiple, post hoc comparisons) from azeliragon relative to placebo on ADAS-cog. Based on the subpopulation data analyses from the Part A study and the prior azeliragon trials, the company will submit a revised Statistical Analysis Plan (SAP) to the Food and Drug Administration for the Part B Study that pre-specifies a target population for the primary study analysis and expects to report Part B topline efficacy results based on 12 month data in June 2018.

  • Key executive leaving High Point biotech firm following disappointing trial results
    American City Business Journals5 months ago

    Key executive leaving High Point biotech firm following disappointing trial results

    The executive is leaving about three weeks after the clinical stage pharmaceutical company announced disappointing trial results for one of its key drug prospects that was aimed at Alzheimer's.

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: vTv Therapeutics and InVivo Therapeutics

    Shares of InVivo also headed higher after a reverse stock split this week. InVivo is also in the process of finalizing a lease assignment that the company expects will result in lease-related savings of approximately $3M through 2019.

  • vTv Therapeutics plans to keep its High Point headquarters despite building sale, clinical setback
    American City Business Journals5 months ago

    vTv Therapeutics plans to keep its High Point headquarters despite building sale, clinical setback

    The prospect of vTv Therapeutics moving its office was raised after it was revealed Cambrex Corp. bought the building. The company is also ending clinical trials for an Alzheimer's drug it has been developing.

  • VTv Therapeutics shares surge 40 percent
    American City Business Journals5 months ago

    VTv Therapeutics shares surge 40 percent

    It's the first day the stock hit above $1 since vTv Therapeutics reported disappointing results from the Phase 3 study of its drug azeliragon.

  • Cambrex, poised for another expansion, buys two properties for $10.2M
    American City Business Journals5 months ago

    Cambrex, poised for another expansion, buys two properties for $10.2M

    Cambrex has taken steps toward another expansion by buying up two buildings for $10.2 million.

  • vTv Therapeutics Crashes on Alzheimer's Drug Study Failure
    Zacks5 months ago

    vTv Therapeutics Crashes on Alzheimer's Drug Study Failure

    vTv Therapeutics (VTVT) shares suffered a major blow when the company's late stage study on lead candidate, azeliragon, for the treatment of Alzheimer's failed.